2022 HAEi Global Leadership Workshop Oct 7, 2022 2:30 PM CEST Supporting Materials Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema 920.1 KB
Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema 920.1 KB
